Posttransplant Autoimmune Hemolytic Anemia with Anti-D Specificity Successfully Treated with Daratumumab: A Case Report
Transfusion Medicine and Hemotherapy · 19.03.2024 · 51 (5) · 355-358
DOI: 10.1159/000535927 ↗Kurz gefasst
Fallbericht in der Zeitschrift Transfusion Medicine and Hemotherapy, online erschienen am 19.03.2024. Verfasst von Filippo Frioni und 11 weiteren Autor:innen. Beteiligte Einrichtung: Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).
Abstract (Originalsprache)
Introduction
Autoimmune hemolytic anemia (AIHA) occurs in 0.7–5.6% of patients undergoing hematopoietic stem cell transplantation, especially from unrelated or haploidentical donor or after lympho-depleted transplant; the majority of cases are represented by warm AIHA, occurring in a full donor chimerism setting. Standard treatments (corticosteroids, intravenous immunoglobulin, splenectomy, rituximab, cyclophosphamide, plasma exchange) lead to lower response rates than those reported in primary AIHA. Daratumumab use has been proposed in many autoimmune conditions (immune thrombocytopenic purpura, aplastic anemia, thrombotic thrombocytopenic purpura, systemic lupus erythematosus, multiple sclerosis), but only few reports have been published on its use for post-HSCT AIHA, mainly in pediatric patients. Case Presentation: We report the successful use of daratumumab in a 68-year-old patient, suffering from post-HSCT AIHA. Five months after Rh-mismatched HSCT, the patient was diagnosed with anti-D AIHA. After first-line treatment (oral prednisone, rituximab, and plasma exchange) failure, being still transfusion-dependent with symptomatic anemia, he underwent treatment with daratumumab, achieving both clinical and laboratory responses.
Discussion
Daratumumab may represent a safe and effective alternative to conventional immunosuppressive therapy, and it deserves further investigations.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Sezione di Ematologia, Dipartimento di Scienze Radiologiche ed Ematologiche, Università Cattolica del Sacro Cuore, Rome, Italy.
- Dipartimento di Diagnostica per Immagini, Radioterapia Oncologica ed Ematologia, Fondazione Policlinico Universitario A. Gemelli IRCCS, Rome, Italy.
Zitieren
APA
Frioni, F., Metafuni, E., Limongiello, M. A., Piccirillo, N., Massini, G., Pellegrino, C., Giammarco, S., Sorà, F., Autore, F., Teofili, L., Sica, S., & Chiusolo, P. (2024). Posttransplant Autoimmune Hemolytic Anemia with Anti-D Specificity Successfully Treated with Daratumumab: A Case Report. Transfusion Medicine and Hemotherapy, 51(5), 355-358. https://doi.org/10.1159/000535927
Vancouver
Frioni F, Metafuni E, Limongiello MA, Piccirillo N, Massini G, Pellegrino C, et al. Posttransplant Autoimmune Hemolytic Anemia with Anti-D Specificity Successfully Treated with Daratumumab: A Case Report. Transfusion Medicine and Hemotherapy. 2024;51(5):355-358. doi:10.1159/000535927
BibTeX
@article{Frioni2024,
author = {Frioni, Filippo and Metafuni, Elisabetta and Limongiello, Maria Assunta and Piccirillo, Nicola and Massini, Giuseppina and Pellegrino, Claudio and Giammarco, Sabrina and Sorà, Federica and Autore, Francesco and Teofili, Luciana and Sica, Simona and Chiusolo, Patrizia},
title = {Posttransplant Autoimmune Hemolytic Anemia with Anti-D Specificity Successfully Treated with Daratumumab: A Case Report},
journal = {Transfusion Medicine and Hemotherapy},
year = {2024},
volume = {51},
number = {5},
pages = {355--358},
doi = {10.1159/000535927}
}
EUVIMED